Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
myFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
    Most Read
    • EU turns to US in scramble for Oxford/AstraZeneca vaccine
    • Biden on brink of passing historic $1.9tn boost to US economy
    • Joe Biden enlists ‘Quad’ allies to counter China
    • Senate approves Joe Biden’s $1.9tn stimulus legislation
    • Mario Draghi makes his mark with vaccine embargo
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • EU turns to US in scramble for Oxford/AstraZeneca vaccine
    • Biden on brink of passing historic $1.9tn boost to US economy
    • Joe Biden enlists ‘Quad’ allies to counter China
    • Airlines redraw routes to match shifting passenger demand
    • Senate approves Joe Biden’s $1.9tn stimulus legislation
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • Airlines redraw routes to match shifting passenger demand
    • Value investor John Rogers sees an end to Big Tech’s stock market dominance
    • Greensill implosion exposes risks of shadow banking
    • Aston Martin promises to make electric models in UK
    • Branson asks UK court to rule on value of Virgin brand
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    Most Read
    • The unravelling of Lex Greensill: a mix of bravado and financial alchemy
    • Fears rise among bond investors as Buffett warns on outlook
    • Will the ECB intensify efforts to keep a lid on bond yields?
    • Emerging markets suffer first outflows since October on rate jump
    • UK investors and companies call for markets reform
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Do young people really need the office?
    • Greensill implosion exposes risks of shadow banking
    • Rishi Sunak takes an axe to Thatcher’s low-tax ideology
    • Wishful thinking on China will not serve American interests
    • Fears rise among bond investors as Buffett warns on outlook
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • Do young people really need the office?
    • Hakluyt seeks to ‘demystify’ in a crowded consultancy market
    • FT business books: March edition
    • Sir Anthony Habgood: Chair’s role ‘is to raise the game of the executive’
    • People: the strongest link in the strained supply chain
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • Inside the ‘Covid Triangle’: a catastrophe years in the making | Free to read
    • The CEO whisperer: ‘Every leader needs a fool’
    • New York state of mind: optimism fuels the property market
    • How gay do you feel?
    • No-lo wine alternatives get the gourmet treatment
  • How to Spend It
  • Sign In
  • Subscribe
  1. Companies
  2. Health
  3. Pharmaceuticals
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • How to Spend It
Financial Times
  • Sign In
  • Subscribe

Pharmaceuticals sector

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Monday, 8 March, 2021
    News in-depthChinese business & finance
    Pharma groups spend billions to tap into booming China healthcare

    Partnerships with local start-ups hit record despite data security and IP protection concerns

  • Sunday, 7 March, 2021
    Covid-19 vaccines
    Most adults in rich nations face long wait for vaccine, distributor warns

    Kuehne+Nagel says production capacity is main limitation to supply of Covid-19 shots

  • Sunday, 7 March, 2021
    Covid-19 vaccines
    Three-quarters of British public would back action to stop Covid jabs monopoly

    Survey findings released as concerns intensify over uneven distribution of vaccines

  • Sunday, 7 March, 2021
    News in-depthCovid-19 vaccines
    The UK biotech racing to cash in on Covid vaccine success

    Oxford Biomedica plans to use earnings from AstraZeneca jab to boost own medicines business

  • Saturday, 6 March, 2021
    Covid-19 vaccines
    EU turns to US in scramble for AstraZeneca vaccine

    Move is part of bloc’s effort to boost faltering immunisation programme

  • Friday, 5 March, 2021
    Covid-19 vaccines
    France backs Italy’s decision to block vaccine exports to Australia

    Canberra urges Brussels to review Rome’s move while also expressing sympathy to EU

  • Friday, 5 March, 2021
    Special ReportFT Health: Future of Antibiotics
    Antibiotic resistance: how to tackle a public health crisis

    Recommendations from two FT roundtables with pharma, government, and NGO experts

  • Thursday, 4 March, 2021
    Covid-19 vaccines
    Germany approves AstraZeneca jab for over-65s

    U-turn could help speed up the country’s sluggish Covid-19 vaccination campaign

  • Thursday, 4 March, 2021
    Covid-19 vaccines
    Italy blocks shipment of Oxford/AstraZeneca vaccines to Australia

    Intervention threatens to increase global tensions over procurement of Covid jabs

  • Promoted Content
  • Thursday, 4 March, 2021
    Coronavirus treatment
    No need for lengthy trials of vaccine modifications, UK regulator says

    Decision makes approval possible in as little as two weeks after final data is received from manufacturers

  • Tuesday, 2 March, 2021
    Covid-19 vaccines
    Biden says US will have enough jabs to vaccinate all adults by end of May

    White House announces accelerated timeline after brokering production deal between J&J and Merck

  • Tuesday, 2 March, 2021
    Covid-19 vaccines
    Covid vaccines show few serious side-effects after millions of jabs

    Surveillance of AstraZeneca and Pfizer recipients in UK reports minor complaints but few severe reactions

  • Tuesday, 2 March, 2021
    Recreational drugs
    Microdosing study shows placebo effect of taking psychedelics

    UK research into LSD consumption reveals expectation of improved wellbeing drives transformation

  • Tuesday, 2 March, 2021
    Special ReportFT 1000: Europe’s Fastest Growing Companies
    FT 1000: the fifth annual list of Europe’s fastest-growing companies

    Green energy supplier takes top spot and London remains the city with the most high-growth businesses

  • Monday, 1 March, 2021
    Covid-19 vaccines
    France lifts restrictions on Oxford/AstraZeneca jab for over-65s

    New data bring about policy shift as other EU countries likely to abandon age limits

  • Monday, 1 March, 2021
    Coronavirus treatment
    Johnson defends UK border regime amid hunt for Covid patient

    News about P.1 variant balanced by data confirming vaccines highly effective at preventing disease

  • Monday, 1 March, 2021
    Covid-19 vaccines
    Austria and Denmark forge ‘vaccine alliance’ with Israel

    EU jab strategy under strain amid growing anxiety over bloc’s slow inoculation drive

  • Monday, 1 March, 2021
    News in-depthCovid-19 vaccines
    After 33 years of failure, Novavax closes in on Covid triumph

    US company prepares to launch its vaccine but the road to success has been long

  • Monday, 1 March, 2021
    News in-depthCovid-19 vaccines
    Hungarians get Chinese Covid vaccine as Orban breaks with EU

    Budapest also orders Russia-made shot despite lack of approval for use within bloc

  • Sunday, 28 February, 2021
    Covid-19 vaccines
    German health advisers signal end of Oxford/AstraZeneca age restrictions

    Similar move expected in France as EU governments come under pressure to clear stockpile of unused vaccines

  • Sunday, 28 February, 2021
    News in-depthCovid-19 vaccines
    China’s vaccination programme beset by delay and reluctance

    International travel restrictions expected until next year

  • Sunday, 28 February, 2021
    Covid-19 vaccines
    FDA authorises Johnson & Johnson’s vaccine in the US

    Regulator gives emergency approval to third Covid treatment and first involving a single shot

  • Saturday, 27 February, 2021
    Johnson & Johnson Co Inc
    Johnson & Johnson’s US vaccine rollout slowed by production problems

    Single-shot jab is third Covid treatment to be authorised in country

  • Saturday, 27 February, 2021
    Covid-19 vaccines
    FDA moves to authorise J&J’s Covid-19 vaccine

    Vote by independent experts paves the way for first single-dose jab in the US

  • Friday, 26 February, 2021
    UK business & economy
    Cancer drug is first to begin fast-track UK approval process

    Approach seeks to cut years off traditional licensing process for treatments

Previous You are on page 1 Next

Topics related to Health & pharmaceuticals

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

FT LiveShare News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingContracts & Tenders
Executive Job SearchAdvertise with the FTFollow the FT on TwitterFT TransactSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School Rankings
Enterprise ToolsNews feedNewslettersCurrency Converter
More from the FT Group
Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2021. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • Americas
    • Middle East and North Africa
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • How to Spend It
  • Special Reports
  • FT recommends
  • Graphics
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In